Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 30;10(9):1053.
doi: 10.3390/antibiotics10091053.

Fungal Biofilms as a Valuable Target for the Discovery of Natural Products That Cope with the Resistance of Medically Important Fungi-Latest Findings

Affiliations
Review

Fungal Biofilms as a Valuable Target for the Discovery of Natural Products That Cope with the Resistance of Medically Important Fungi-Latest Findings

Estefanía Butassi et al. Antibiotics (Basel). .

Abstract

The development of new antifungal agents that target biofilms is an urgent need. Natural products, mainly from the plant kingdom, represent an invaluable source of these entities. The present review provides an update (2017-May 2021) on the available information on essential oils, propolis, extracts from plants, algae, lichens and microorganisms, compounds from different natural sources and nanosystems containing natural products with the capacity to in vitro or in vivo modulate fungal biofilms. The search yielded 42 articles; seven involved essential oils, two Brazilian propolis, six plant extracts and one of each, extracts from lichens and algae/cyanobacteria. Twenty articles deal with the antibiofilm effect of pure natural compounds, with 10 of them including studies of the mechanism of action and five dealing with natural compounds included in nanosystems. Thirty-seven manuscripts evaluated Candida spp. biofilms and two tested Fusarium and Cryptococcus spp. Only one manuscript involved Aspergillus fumigatus. From the data presented here, it is clear that the search of natural products with activity against fungal biofilms has been a highly active area of research in recent years. However, it also reveals the necessity of deepening the studies by (i) evaluating the effect of natural products on biofilms formed by the newly emerged and worrisome health-care associated fungi, C. auris, as well as on other non-albicans Candida spp., Cryptococcus sp. and filamentous fungi; (ii) elucidating the mechanisms of action of the most active natural products; (iii) increasing the in vivo testing.

Keywords: Candida spp.; Cryptococcus spp.; Fusarium spp.; antifungal resistance; filamentous fungi; fungal biofilm; mechanisms of antibiofilm action; natural products.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(a) The five-stage process involved in the development of biofilm: 1. adherence of yeasts to a surface followed by yeast-to-hyphal transition; 2. the exopolymeric matrix (EPM) is produced resulting in a firmly adhered “irreversible” attachment; 3. early biofilm architecture is developed; 4. the biofilm reaches maturation in a three-dimensional structure and 5. single planktonic cells are dispersed from the mature biofilm. Reproduced from Stoodley et al., 2002 [49]. Image credit: D. Davies, with permission of Prof. David Davies. (b) A clearer scheme of stage 1. Yeasts adhere to host cell surfaces. Contact to host cells triggers the yeast-to-hyphal transition and directed growth via thigmotropism. Reproduced from part of Figure 1a from Mayer et al. [51], with permission. (c) A scan electron microscopy (SEM) image of a mature (48 h) Candida albicans biofilm (formed in stage 4 of Figure 1a). Bar = 10 µm. Yeasts, hyphae, and pseudohyphae can be observed. Most EPM was lost during the SEM procedures. Reproduced from Ramage et al. [50] with permission.

Similar articles

Cited by

References

    1. Pathakumari B., Liang G., Liu W. Immune defence to invasive fungal infections: A comprehensive review. Biomed. Pharmacother. 2020;130:110550. doi: 10.1016/j.biopha.2020.110550. - DOI - PubMed
    1. Wuyts J., Van Dijck P., Holtappels M. Fungal persister cells: The basis for recalcitrant infections? PLoS Path. 2018;14:e1007301. doi: 10.1371/journal.ppat.1007301. - DOI - PMC - PubMed
    1. Nicola A.M., Albuquerque P., Paes H.C., Fernandes L., Costa F.F., Kioshima E.S., Abadio A.K.R., Bocca A.L., Felipe M.S. Antifungal drugs: New insights in research & development. Pharmacol. Ther. 2019;195:21–38. - PubMed
    1. Kullberg B.J., Vasquez J., Mootsikapun P., Nucci M., Paiva J.-A., Garbino J., Yan J.L., Aram J., Capparella M.R., Conte U. Efficacy of anidulafungin in 539 patients with invasive candidiasis: A patient-level pooled analysis of six clinical trials. J. Antimicrob. Chemother. 2017;72:2368–2377. doi: 10.1093/jac/dkx116. - DOI - PMC - PubMed
    1. Bongomin F., Gago S., Oladele R.O., Denning D.W. Global and multi-national prevalence of fungal diseases—Estimate precision. J. Fungi. 2017;3:57. doi: 10.3390/jof3040057. - DOI - PMC - PubMed

LinkOut - more resources